Show simple item record

dc.contributor.authorValldeoriola, Francesc
dc.contributor.authorCatalán, María José
dc.contributor.authorEscamilla-Sevilla, Francisco
dc.contributor.authorFreire, Eric
dc.contributor.authorOlivares, Jesús
dc.contributor.authorCubo, Esther
dc.contributor.authorGarcía, Diego Santos
dc.contributor.authorCalopa, Matilde
dc.contributor.authorMartínez-Martín, Pablo 
dc.contributor.authorParra, Juan Carlos
dc.contributor.authorArroyo, Gloria
dc.contributor.authorArbelo, José Matías
dc.identifier.citationNPJ Parkinsons Dis. 2021 Nov 30;7(1):108.es_ES
dc.description.abstractLevodopa-carbidopa intestinal gel (LCIG) has shown to be efficacious in motor and non-motor symptoms (NMS). Nevertheless, studies with patient Quality of Life (QoL) as a primary endpoint are scarce. To assess the effect of LCIG on Advanced Parkinson's Disease (APD) patients QoL. Secondarily, the impact on motor symptoms and NMS, emotional well-being, treatment satisfaction, and caregiver QoL, stress, disease burden, anxiety, depression, and work impairment were also investigated. In this prospective, 6-month multicenter postmarketing observational study, LCIG was administered to 59 patients with APD. Endpoints were assessed using validated scales and questionnaires. LCIG significantly improved patient QoL (PDQ-39 mean change ± standard deviation from baseline, -12.8 ± 14.6; P < 0.0001), motor symptoms (UPDRS-III in "On," -6.5 ± 11.8; P = 0.0002), NMS (NMSS, -35.7 ± 31.1; P < 0.0001), mood (Norris/Bond-Lader VAS, -6.6 ± 21.1; P = 0.0297), fatigue (PFS-16, -0.6 ± 1.0; P = 0.0003), depression (BDI-II, -5.1 ± 9.4; P = 0.0002), anxiety (BAI, -6.2 ± 9.6; P < 0.0001), and patient treatment satisfaction (SATMED-Q, 16.1 ± 16.8; P < 0.0001). There were significant correlations between the change from baseline to 6 months between PDQ-39 and UPDRS-IV, NMSS, BAI, BDI-II, AS, and PFS-16 scores, and Norris/Bond-Lader alertness/sedation factor. Caregiver anxiety also improved (Goldberg anxiety scale, -1.1 ± 1.0; P = 0.0234), but the clinical relevance of this finding is questionable. The serious adverse events reported were similar to those previously described for LCIG. In patients with APD, LCIG improves QoL, motor symptoms and NMS, emotional well-being, and satisfaction with the treatment. Improvement in patient QoL is associated with improvements in motor complications, NMS, anxiety, depression, apathy and fatigue. Improvements in patients' QoL does not correspond with improvements in caregivers' QoL or burden.es_ES
dc.description.sponsorshipThe study was sponsored by AbbVie, S.L.U. The design, study conduct, and financial support for the ADEQUA study were provided by AbbVie. AbbVie participated in the research, data collection, analysis and interpretation of data, writing, reviewing, and approving the publication.es_ES
dc.publisherNature Publishing Group es_ES
dc.subjectParkinson's diseasees_ES
dc.titlePatient and caregiver outcomes with levodopa-carbidopa intestinal gel in advanced Parkinson's diseasees_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.contributor.funderAbbVie es_ES
dc.identifier.journalNPJ Parkinson's Diseasees_ES
dc.repisalud.centroISCIII::Centro Nacional de Epidemiologíaes_ES
dc.rights.accessRightsopen accesses_ES

Files in this item

Acceso Abierto
Acceso Abierto

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional